These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 11669554)
1. Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil. Lauro VD; Spazzapan S; Lombardi D; Paolello C; Scuderi C; Crivellari D; Magri MD; Veronesi A Tumori; 2001; 87(1):27-9. PubMed ID: 11669554 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338 [TBL] [Abstract][Full Text] [Related]
3. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study. Bisagni G; Boni C; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A; Savoldi L Tumori; 1998; 84(6):659-61. PubMed ID: 10080671 [TBL] [Abstract][Full Text] [Related]
4. A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. Michelotti A; Salvadori B; Donati S; Tognoni A; Tibaldi C; Conte PF Tumori; 1997; 83(5):826-8. PubMed ID: 9428916 [TBL] [Abstract][Full Text] [Related]
5. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153 [TBL] [Abstract][Full Text] [Related]
6. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Pieńkowski T; Jagiello-Gruszfeld A Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140 [TBL] [Abstract][Full Text] [Related]
8. Continuous infusion fluorouracil in the management of advanced breast cancer: a phase II study. Crivellari D; Magri MD; Buonadonna A; Lombardi D; Paolello C; De Cicco M; Fantin D; Veronesi A Tumori; 2000; 86(1):42-5. PubMed ID: 10778765 [TBL] [Abstract][Full Text] [Related]
9. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Regazzoni S; Pesce G; Marini G; Cavalli F; Goldhirsch A Ann Oncol; 1996 Oct; 7(8):807-13. PubMed ID: 8922194 [TBL] [Abstract][Full Text] [Related]
10. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. Bellmunt J; Eres N; Ribas A; Casado S; Albanell J; Baselga J Cancer Chemother Pharmacol; 1997; 40(3):273-6. PubMed ID: 9219513 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies. Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F Oncology; 2001; 60(2):116-22. PubMed ID: 11244325 [TBL] [Abstract][Full Text] [Related]
13. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179 [TBL] [Abstract][Full Text] [Related]
14. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. Frustaci S; Buonadonna A; Romanini A; Comandone A; Dalla Palma M; Gamucci T; Verusio C; Lionetto R; Dani C; Casali P; Santoro A Tumori; 1999; 85(4):229-33. PubMed ID: 10587022 [TBL] [Abstract][Full Text] [Related]
15. Acceptance of external infusion pumps in patients with advanced breast cancer receiving continuous infusion fluorouracil. Lombardi D; Di Lauro V; Piani B; Scuderi C; Spazzapan S; Magri MD; Crivellari D; Annunziata MA; De Cicco M; Veronesi A Tumori; 2003; 89(5):488-91. PubMed ID: 14870769 [TBL] [Abstract][Full Text] [Related]
16. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Nolè F; Munzone E; Mandalà M; Catania C; Orlando L; Zampino MG; Minchella I; Colleoni M; Peruzzotti G; Marrocco E; Goldhirsch A Ann Oncol; 2001 Jan; 12(1):95-100. PubMed ID: 11249057 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro J; Bellmunt J; Arranz F; Valentí V; Escudero P; Menéndez D; Casado A; Poveda A Ann Oncol; 1998 Aug; 9(8):871-6. PubMed ID: 9789610 [TBL] [Abstract][Full Text] [Related]
18. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362 [TBL] [Abstract][Full Text] [Related]
19. Intermittent continuous infusion of fluorouracil and low-dose oral leucovorin in pretreated breast cancer: a pilot study. Colleoni M; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P Tumori; 1997; 83(3):665-8. PubMed ID: 9267485 [TBL] [Abstract][Full Text] [Related]
20. 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. Brain EC; Mita A; Soulié P; Errihani H; Hardy Bessard AC; Chaouche M; Alexandre J; Delord JP; Cvitkovic E; Jasmin C; Misset JL J Cancer Res Clin Oncol; 1997; 123(4):227-31. PubMed ID: 9177496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]